Regeneron Pharmaceuticals Inc (REGN)
Regeneron Pharmaceuticals Inc (REGN) carries a ŷRobot AI score of 63 out of 100. The model's fair value estimate is $998.30, 4.5% above the last close of $955.47. The chart signal reads Bearish.
| Metric | REGN |
|---|---|
| AI score | 63 / 100 |
| Chart signal | Bearish |
| Fair value estimate | $998.30 |
| Upside to fair value | 4.5% |
| Previous close | $955.47 |
| P/E | 21.25 |
| Price / sales | 5.85 |
| Market cap | $98.40B |
| EPS | 45.24 |
| Revenue growth | 5.6% |
| 1-year price change | 5.8% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about REGN
Is REGN overvalued or undervalued right now?
As of Nov 3, 2026, ŷRobot's fair-value model estimates Regeneron Pharmaceuticals Inc (REGN) at $998.30 against a last close of $955.47, implying 4.5% upside to the model's estimate.
Is REGN's chart signal bullish or bearish?
The chart-signal model classifies REGN as Neutral as of Nov 14, 2026, with a signal score of -0.10 on a -1 to 1 scale.
What is REGN's ŷRobot AI score?
REGN scores 63 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 14, 2026.
Is REGN stock expensive on P/E and P/S?
REGN trades at 21.2 times earnings and 5.9 times sales as of Nov 14, 2026.
What does REGN's seasonal forecast show?
ŷRobot's seasonal forecast curve for REGN reads -0.7% at 30 days, +0.8% at 90 days, and +5.8% at one year as of Nov 14, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is REGN growing?
Regeneron Pharmaceuticals Inc's revenue growth is +5.6% and free-cash-flow growth is +18.5% on the latest reported figures.
REGN chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.